EMD Serono Names Oncology VPs

From DCAT Value Chain Insights (VCI)

By People On The Move posted 06-02-2015 12:08


EMD Serono, the US biopharmaceutical business of Merck KGaA, has made two management appointments in oncology.

David Trexler, senior vice president of Oncology Commercial, will lead the strategy of the EMD Serono oncology franchise and will be responsible for maximizing growth opportunities by building a performance-driven oncology team focused on customer and patient centricity. He has more than 25 years of experience in branded pharmaceutical marketing, sales and business development. He joins EMD Serono from Eisai, Inc., where he served as senior vice president of the Americas Oncology Business Unit. At Eisai, Mr. Trexler successfully led the oncology sales and marketing teams, expanding Eisai’s reach in strategic markets across the Americas. Mr. Trexler previously held senior leadership roles at Mylan Bertek Pharmaceuticals and Sanofi-Aventis Pharmaceuticals.

Dr. Zhen Su, vice president of Oncology Medical, will lead the medical strategy and team for the franchise. A physician executive with more than 15 years of experience, Dr. Su has strong clinical expertise in oncology, immuno-oncology and urology. He has held positions in academic and pharmaceutical medicine, including general management, clinical development, medical affairs and business development. Prior to EMD Serono, Dr. Su served as associate vice president and global head of Jevtana®(cabazitaxel) at Sanofi. Prior to joining industry, Dr. Su held several academic positions, including Assistant Professor of Surgery at Duke University, where he also received his fellowship in oncology.

Source: EMD Serono


Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT). 

Learn more and sign up to receive a complimentary subscription